Associations and prognostic implications of Eastern Cooperative Oncology Group performance status and tumoral LINE-1 methylation status in stage III colon cancer patients

Table 5 The association between LINE-1 methylation status and clinicopathological parameters (stage III colon cancers only)

Parameters	LINE-1 methylation levels (low vs.high)
	Cancer sample (n = 268)			Normal LN sample (n = 268)
	OR	(95 % C.I.)	P ^a	OR	(95 % C.I.)	P ^a
Gender (male vs. female)	1.63	(0.971–2.747)	0.065	1.11	(0.699–1.745)	0.670
Age (≥60 years vs. <60 years)	1.23	(0.742–2.053)	0.419	0.97	(0.624–1.508)	0.893
BMI (overweight vs. normal)	1.21	(0.711–2.044)	0.487	1.56	(0.991–2.444)	0.055
Tumor location (distal vs. proximal)	0.78	(0.438–1.383)	0.393	1.14	(0.694–1.887)	0.598
Pathology
(Mucinous vs. non-mucinous)	0.77	(0.149–4.004)	0.759	1.52	(0.361–6.387)	0.569
Differentiation
(High grade vs. low grade)	0.58	(0.154–2.185)	0.420	0.51	(0.154–1.687)	0.270
T stage (T4 vs. T1, 2, 3)	0.99	(0.417–2.359)	0.985	0.74	(0.381–1.447)	0.382
N stage (N2 vs. N0, 1)	1.07	(0.600–1.921)	0.812	1.21	(0.720–2.039)	0.470
Microsatellite status
(MSI-H vs. MSS + MSI-L)	0.40	(0.118–1.388)	0.150	1.02	(0.380–2.728)	0.972
Performance status (PS ≥ 1 vs. PS = 0)	1.80	(1.081–3.004)	0.024	1.20	(0.770–1.871)	0.421

BMI body mass index, MSS microsatellite stable, MSI-L microsatellite instability-low, MSI-H microsatellite instability-high, PS performance status
^aUnconditional logistic regression, adjusted for other selected covariates

ISSN: 1868-7083